GSK is leading the pharmaceutical sector by being first in Australia to introduce a new framework for its medical education program and interactions with healthcare professionals to increase transparency.
These press releases are intended for business journalists and analysts/investors
Australian manufacturing innovation starts pilot with the hope it could reduce cost of vaccination in developing world
- Assistant Minister for Science Karen Andrews opens new vaccine facility in Boronia, Victoria
- GSK awarded $1 million Federal Government grant for advanced manufacturing project
- Three-year pilot to test commercialisation
Amgen and GSK to Work Together to Ensure a Smooth Transition for
Prolia® Patients and Their Physicians
Winning research team unlocks immune system secret - specialised T cells attack microbes as they make their vitamins
Australian researchers awarded $80,000 for breakthrough in immunity
Millions more children from the world’s poorest countries are being vaccinated against more diseases than ever before.
GSK Australia is proud to be partnering with the Australian Government to provide a quadrivalent (four-strain) influenza vaccine for the National Immunisation Program (NIP) for the 2016 season.
Dr Ginni Mansberg ambassador for ‘Tried-It-All’ hay fever campaign launched today
Pharmacy Level Recall - Bactroban® Cream (mupirocin calcium 2%) and Bactroban® Nasal Ointment (mupirocin calcium 2%)
Recall of five batches of Bactroban Cream and three batches of Bactroban Nasal Ointment
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.